Platelet Function in Patients with Septic Shock

Products & Services
Catalog
- PepMix™ Peptide Pools
  PepMix™ Peptide Pools
  Pools of overlapping peptides from antigenic proteins for T-cell stimulation, T-cell expansion in T-cell assays such as ELISPOT, ICS or Flow Cytometry, e.g. for immune monitoring.
- Transduction Enhancer
  
  Transduction Enhancer
  Protransduzin™ the highly efficient transduction enhancer increases viral gene transfer in pre-clinical and clinical applications, such as ex vivo gene therapy and CAR-T cell development.
- Antigen Peptides
  - COVID-19 Antigen Peptides
  - Further Antigen Peptides
  Antigen Peptides
  Antigen peptides represent specific epitopes for stimulation of T cells in T cell assays such as ELISPOT. We offer the corresponding MHC multimer for each antigen peptide. Antigens from different pathogens are available as well as tumor associated antigens.
- MHC Multimers
  MHC Multimers
  MHC Multimers for reproducible detection, enumeration and isolation of antigen-specific T cells with disease specific peptides.
- Proteomics Peptides & Kits
  Proteomics Peptides & Kits
  Peptide sets and pools, as well as assay standardization kits are available with stable isotope labeled or unlabeled proteotypic peptides for mass-spectrometry based proteomics such as MRM assays.
- RepliTope™ Peptide Microarrays
  RepliTope™ Peptide Microarrays
  Peptide microarrays that display overlapping peptide scans through antigens from infectious organisms or tumor associated antigens for antibody or serum profiling.
- Chelate Peptides (DOTA)
  
  Chelate Peptides (DOTA)
  DOTA is linked to molecules that have affinity for various structures (e.g. somatostatin receptors in neuroendocrine tumors). The resulting compounds can be bound to radionuclided and are used with a number of radioisotopes in cancer therapy and diagnosis
- Cosmetic Peptides (DPRA Peptides)
  
  Cosmetic Peptides
  Cosmetic Peptides such as Lysine and Cysteine Peptide are used for DPRA (Direct Peptide Reactivity Assay) for Skin Sensitization Testing. The DPRA measures the reaction of a chemical with synthetic peptides containing Cysteine (Ac‑RFAACAA‑COOH) or Lysine (Ac‑RFAAKAA‑COOH) to assess its sensitization potency. For research use only!
- Abeta & Prion Peptides
  - Amyloid Beta A4 Peptides
  - Major Prion Peptides
  Abeta & Prion Peptides
  Purified, fully analyzed, high quality peptides, synthesized from the peptide experts for Alzheimers and prion research.
- Assay Services
  
  Assay Services
  We offer our extensive know-how and experience in peptide microarray incubation & data evaluation as full-service packages for many applications.
- Enzyme Substrates
  Enzyme Substrates
  Large collections of peptidic enzyme substrates in microtiter plates or displayed on microarrays for screening and enyzme profiling.
- Histone Peptide Tools
  Histone Peptide Tools
  Our histone peptide library is the largest on the market and available as Peptide ELISA, Peptide Microarray or sets of histone peptides
Contract Research
Company
- - JPT has a work force of >100 highly trained and skilled employees. 30 of our co-workers hold a university degree and 20 have a PhD in natural sciences.
News & Publications
Support & Contact
- - We take pride in our competent service and swift response. Please do not hesitate to contact us for further information. We also very much welcome your feedback and comments.

Platelet Function in Patients with Septic Shock

Mathies Appel Laursen et al., Thrombosis Research (2019) - PMID: 31756573

Product(s) used in this publication: Absolutely Quantified Peptides SpikeTides™ TQL

Abstract

INTRODUCTION:

Plateletfunction during sepsis-related disseminated intravascular coagulation (DIC) is only sparsely investigated. We aimed to determine 1) platelet aggregation, independently of platelet count, and platelet activation among septic shockpatients and 2) whether platelet aggregation or platelet activation differed among patients with and without DIC.

MATERIALS AND METHODS:

We included 38 septic shockpatients at the Intensive Care Unit, Aarhus University Hospital, Denmark. Blood samples were obtained within 24 h of admission and the two consecutive days. Platelet aggregation was measured by impedance aggregometry including a model defining expected platelet aggregation relative to platelet count. Platelet activation was measured employing flow cytometry.

RESULTS:

Platelet aggregation was significantly lower in septic shockpatients than in healthy controls (p < .0001) and was lower in patients with DIC than in patients without DIC (p < .05). However, patients with septic shock, regardless of DIC-status, had platelet aggregation as expected for their platelet counts and were within the 95% prediction interval calculated from healthy controls. Platelet activation was significantly higher in septic shockpatients than in healthy controls indicated by higher platelet surface-bound fibrinogen and CD63 (p < .05). Surface-bound P-selectin was significantly lower among septic shockpatients than in healthy controls (p < .001), but plasma soluble P-selectin was significantly higher among septic shockpatients than in healthy controls (p < .0001).

CONCLUSION:

Patients with septic shock displayed no impairment of platelet aggregation when interpreted relative to platelet count. Platelet activation, measured with flow cytometry, was increased among septic shockpatients compared with healthy controls.

Search

All Our Publications